RPRX vs. CFG, ESS, EG, L, NMR, MAA, NTRS, BAM, HOOD, and AEG
Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Citizens Financial Group (CFG), Essex Property Trust (ESS), Everest Group (EG), Loews (L), Nomura (NMR), Mid-America Apartment Communities (MAA), Northern Trust (NTRS), Brookfield Asset Management (BAM), Robinhood Markets (HOOD), and Aegon (AEG). These companies are all part of the "finance" sector.
Citizens Financial Group (NYSE:CFG) and Royalty Pharma (NASDAQ:RPRX) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.
Royalty Pharma has a net margin of 35.70% compared to Royalty Pharma's net margin of 11.52%. Citizens Financial Group's return on equity of 22.94% beat Royalty Pharma's return on equity.
Citizens Financial Group pays an annual dividend of $1.68 per share and has a dividend yield of 4.5%. Royalty Pharma pays an annual dividend of $0.84 per share and has a dividend yield of 3.1%. Citizens Financial Group pays out 60.9% of its earnings in the form of a dividend. Royalty Pharma pays out 62.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 4 consecutive years. Citizens Financial Group is clearly the better dividend stock, given its higher yield and lower payout ratio.
Citizens Financial Group received 204 more outperform votes than Royalty Pharma when rated by MarketBeat users. However, 67.96% of users gave Royalty Pharma an outperform vote while only 62.58% of users gave Citizens Financial Group an outperform vote.
Citizens Financial Group has higher revenue and earnings than Royalty Pharma. Citizens Financial Group is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Citizens Financial Group had 8 more articles in the media than Royalty Pharma. MarketBeat recorded 14 mentions for Citizens Financial Group and 6 mentions for Royalty Pharma. Citizens Financial Group's average media sentiment score of 1.01 beat Royalty Pharma's score of 0.39 indicating that Royalty Pharma is being referred to more favorably in the news media.
Citizens Financial Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
Citizens Financial Group currently has a consensus price target of $37.73, indicating a potential upside of 1.54%. Royalty Pharma has a consensus price target of $46.75, indicating a potential upside of 71.43%. Given Citizens Financial Group's stronger consensus rating and higher probable upside, analysts plainly believe Royalty Pharma is more favorable than Citizens Financial Group.
94.9% of Citizens Financial Group shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 0.6% of Citizens Financial Group shares are owned by company insiders. Comparatively, 18.7% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Royalty Pharma beats Citizens Financial Group on 11 of the 21 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Royalty Pharma Competitors List
Related Companies and Tools